FLUIMUCIL 600 mg EFFERVESCENT TABLETS

Fluimucil 600 mg effervescent tablets contain 600 mg of acetylcysteine per tablet. Acetylcysteine is a mucolytic medicine that reduces the viscosity of thick bronchial mucus and makes it easier to clear by coughing.

This strength and pharmaceutical form are intended only for adults with acute or chronic respiratory conditions accompanied by excessive production of thick mucus and difficulty expectorating.

Fluimucil 600 mg – uses, dosage and precautions

What is Fluimucil 600 used for?

Fluimucil 600 is used for respiratory disorders associated with excessive production of thick, viscous mucus, including:

• acute bronchitis;
• chronic bronchitis and its exacerbations;
• bronchiectasis;
• pulmonary emphysema;
• cystic fibrosis.

Acetylcysteine breaks chemical bonds that contribute to mucus viscosity, making the mucus thinner and easier to cough up. It does not treat the underlying cause of a respiratory infection and does not replace an antibiotic when antibiotic treatment is required.

How is Fluimucil 600 taken?

The maximum total daily dose is 600 mg of acetylcysteine. Do not take another medicine or supplement containing acetylcysteine or NAC at the same time unless a doctor or pharmacist has checked the total daily amount.

Place the tablet in half a glass of water, allow it to dissolve completely and drink the entire solution immediately. Do not mix the prepared solution with other medicines.

A mild sulphur-like smell is characteristic of acetylcysteine and does not mean that the medicine has deteriorated.

How long is treatment continued?

For acute symptoms, treatment generally lasts 5 to 10 days. Consult a doctor if symptoms persist, recur or become worse.

Treatment lasting longer than 10 days, including prolonged treatment for chronic respiratory conditions, must be prescribed and supervised by a doctor.

When must Fluimucil 600 not be used?

• if you are allergic to acetylcysteine or any other ingredient;
• in children under two years of age, in whom mucolytic medicines are contraindicated;
• during pregnancy or breastfeeding without a doctor's explicit decision and supervision;
• together with cough suppressants unless specifically directed by a doctor.

Although the general contraindication for acetylcysteine includes children under two years of age, the specific Fluimucil 600 mg pack is labelled for adults only.

When is additional caution required?

Consult a doctor or pharmacist before use if you:

• have bronchial asthma;
• have or previously had a stomach or duodenal ulcer;
• take medicines that irritate the gastrointestinal mucosa;
• have histamine intolerance;
• have difficulty coughing up increased amounts of mucus;
• need to restrict your sodium intake;
• have phenylketonuria or intolerance to certain sugars.

At the beginning of treatment, the mucus may become thinner but its volume may increase. Medical advice is required if the patient cannot cough it up effectively.

Stop treatment immediately if bronchospasm, choking or breathing difficulty develops.

Interactions with other medicines

• Cough suppressants: reduced cough reflex may cause mucus retention.
• Antibiotics: oral antibiotics and acetylcysteine should be taken at least two hours apart. This does not apply to loracarbef.
• Activated charcoal: may reduce the effect of acetylcysteine.
• Nitroglycerin: combined use may cause a marked reduction in blood pressure and headache.

Acetylcysteine may interfere with certain laboratory tests for salicylates in the blood and ketone bodies in the urine. Tell the healthcare professional that you are using Fluimucil before testing.

Pregnancy and breastfeeding

Do not use Fluimucil 600 on your own during pregnancy or breastfeeding. It may be used only when a doctor considers it necessary and under direct medical supervision.

Possible side effects

Uncommon effects include hypersensitivity, headache, ringing in the ears, rapid heartbeat, nausea, vomiting, diarrhoea, abdominal pain, inflammation of the mouth, rash, itching, hives, angioedema, fever and reduced blood pressure.

Rare effects include bronchospasm, difficulty breathing and indigestion.

Very rare effects include severe allergic reactions and bleeding. Very rare serious skin and mucosal reactions, including Stevens–Johnson syndrome and Lyell syndrome, have also been reported.

Sodium, aspartame and glucose

• Each tablet contains 156.9 mg of sodium, equivalent to approximately 7.8% of the recommended maximum daily sodium intake for an adult.
• The medicine contains aspartame, a source of phenylalanine that may be harmful to patients with phenylketonuria.
• The lemon flavour contains glucose.

Patients who must restrict sodium, have phenylketonuria or have been diagnosed with intolerance to certain sugars should seek advice before use.

Composition, pack and manufacturer

• Active ingredient: 600 mg of acetylcysteine per effervescent tablet.
• Other ingredients: anhydrous citric acid, sodium hydrogen carbonate, aspartame E951 and lemon flavour containing glucose.
• Pharmaceutical form: round, white effervescent tablet.
• Pack size: 10 effervescent tablets in five strips of two tablets.
• Marketing authorisation holder: Bonifar d.o.o. Novi Beograd, Serbia.
• Manufacturer: Zambon Switzerland Ltd, Switzerland.
• ATC code: R05CB01.
• Supply status in Serbia: available without a prescription.

Storage

Keep out of the sight and reach of children and retain the medicine in its original packaging. No special temperature conditions are required.

Drink the prepared solution immediately. Do not use the medicine after the expiry date stated on the packaging.

Related category and educational guide

Explore: Expectorant products and productive cough support.

For more information about dry and productive cough, see the Serbian-language guide: How to stop a cough quickly and easily.

Related products and alternatives

Important: NAC products are listed as related alternatives, not as products to take together. Combining them may unnecessarily exceed the intended total daily acetylcysteine dose.

Source: Patient information leaflet, Summary of Product Characteristics and packaging text approved by the Serbian Medicines and Medical Devices Agency – ALIMS. View the official patient leaflet.
Leaflet last approved: February 2023. Source checked: 2 August 2026.

This information does not replace medical assessment, professional advice or the original patient leaflet supplied with the medicine.